BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 21067806)

  • 1. Is intensive LDL-cholesterol lowering beneficial and safe?
    Cheung BM; Lam KS
    Lancet; 2010 Nov; 376(9753):1622-4. PubMed ID: 21067806
    [No Abstract]   [Full Text] [Related]  

  • 2. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
    Olsson AG
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
    [No Abstract]   [Full Text] [Related]  

  • 3. [Statins plus cholesterol resorption inhibitor. LDL goal values attainable].
    MMW Fortschr Med; 2002 Sep; 144(38):56. PubMed ID: 12395708
    [No Abstract]   [Full Text] [Related]  

  • 4. Lipid-lowering study raises issues of therapy's value.
    Thompson CA
    Am J Health Syst Pharm; 2008 Apr; 65(7):594-5. PubMed ID: 18359962
    [No Abstract]   [Full Text] [Related]  

  • 5. [Statin and absorption inhibitor work synergistically. More risk patient reach LDL cholesterol goal value].
    MMW Fortschr Med; 2007 Apr; 149(17):56-7. PubMed ID: 17674912
    [No Abstract]   [Full Text] [Related]  

  • 6. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Say no to the extremes in the debate on lipid reduction].
    Hjemdahl P; Allhammar A; Eklund J; Forslund T; Hulting J; Kahan T; Martinsson A; Malmström R; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2011 Sep 7-13; 108(36):1664-5. PubMed ID: 22032007
    [No Abstract]   [Full Text] [Related]  

  • 8. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
    Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF
    Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Strengthened support for statin therapy as secondary prevention. Doubtful evidence for more intensive lowering of cholesterol levels].
    Håkansson J
    Lakartidningen; 2011 Jun 1-14; 108(22-23):1234-5. PubMed ID: 21786497
    [No Abstract]   [Full Text] [Related]  

  • 10. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Breuer HW
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2201; author reply 2202. PubMed ID: 20979008
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol in patients with primary hypercholesterolemia.
    Yoon HS; Kim SH; Kim JK; Ko SH; Ko JE; Park SJ; Park MG; Lee JH; Hyon MS
    Ann Pharmacother; 2011 Jul; 45(7-8):841-9. PubMed ID: 21693699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ezetimib as combination partner in hypercholesteremia. Lowering LDL beyond the effect of statins].
    Sudhop T; von Bergmann K
    MMW Fortschr Med; 2003 Apr; 145(16):48-50. PubMed ID: 14606402
    [No Abstract]   [Full Text] [Related]  

  • 13. Improve-it: Full disclosures?
    Nicot P; Guerbaai RA; Ennezat PV
    Int J Cardiol; 2015 Dec; 201():380-1. PubMed ID: 26310982
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
    Averna M; Missault L; Vaverkova H; Farnier M; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Taggart W; Brudi P
    Diab Vasc Dis Res; 2011 Oct; 8(4):262-70. PubMed ID: 21859750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
    Klose G
    MMW Fortschr Med; 2004 Jun; 146(26):14. PubMed ID: 15529683
    [No Abstract]   [Full Text] [Related]  

  • 16. LDL-Cholesterol is the King.
    Goumas GS
    Angiology; 2009; 60(3):387-8. PubMed ID: 19497926
    [No Abstract]   [Full Text] [Related]  

  • 17. Simvastatin + ezetimibe: a combination with no proven advantages.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17460829
    [No Abstract]   [Full Text] [Related]  

  • 18. [Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
    MMW Fortschr Med; 2005 Aug; 147(33-34):50-1. PubMed ID: 16138640
    [No Abstract]   [Full Text] [Related]  

  • 19. LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?
    Besseling J; van Capelleveen J; Kastelein JJ; Hovingh GK
    Drugs; 2013 Mar; 73(4):293-301. PubMed ID: 23494186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lowering LDL cholesterol is good, but how and in whom?
    Stone NJ; Lloyd-Jones DM
    N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.